Persistent varices in cured patients: Understanding the role of hepatic venous pressure gradient.

Cirrhosis recompensation Cirrhosis regression Etiologic factor removal Portal hypertension WHVP

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 26 03 2024
revised: 04 07 2024
accepted: 15 07 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Etiologic factor removal (ER) drives recompensation and improves portal hypertension in cirrhosis. Esophageal varices (EV) and portosystemic shunts (PSS) have been found in patients despite hepatic venous pressure gradient (HVPG) dropping below 10 mmHg after ER, questioning HVPG accuracy in reflecting true portal pressure in the setting of ER. We aim to evaluate the correlation of HVPG with direct portal pressure (DPP) in patients with persistence of EV after ER despite HVPG <10 mmHg. This is a bicentric 'proof of concept' study evaluating HVPG and ultrasound-guided percutaneous DPP in patients with HCV or alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER. Seven patients with HCV and three with alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER were included. At evaluation, all patients had a patent portal vein and were compensated. The median platelet count was 129.5 (IQR 95-145) × 10 HVPG accurately reflects PPG in the context of HCV and alcohol-related cirrhosis regression. After ER, EV may persist despite HVPG <10 mmHg. The benefit of prophylaxis in patients with EV and HVPG <10 mmHg is unknown. Future studies with clinical endpoints are needed to validate our findings. Despite a favorable evolution after the removal of the etiologic factor, varices persist in some patients, and there is a lack of concise guidelines for the evaluation and management of portal hypertension in this population. Our research underscores the persistence of varices in the absence of clinically significant portal hypertension and significantly demonstrates the accuracy of hepatic venous pressure gradient (HVPG) in reflecting portal vein pressure in this specific patient group. These findings emphasize the crucial role of HVPG in the assessment of portal hypertension after etiologic factor removal and lay the groundwork for further investigation into clinical outcomes and the necessity of non-selective beta-blockers in individuals with persistent varices after the removal of etiologic factor.

Sections du résumé

Background & Aims UNASSIGNED
Etiologic factor removal (ER) drives recompensation and improves portal hypertension in cirrhosis. Esophageal varices (EV) and portosystemic shunts (PSS) have been found in patients despite hepatic venous pressure gradient (HVPG) dropping below 10 mmHg after ER, questioning HVPG accuracy in reflecting true portal pressure in the setting of ER. We aim to evaluate the correlation of HVPG with direct portal pressure (DPP) in patients with persistence of EV after ER despite HVPG <10 mmHg.
Methods UNASSIGNED
This is a bicentric 'proof of concept' study evaluating HVPG and ultrasound-guided percutaneous DPP in patients with HCV or alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER.
Results UNASSIGNED
Seven patients with HCV and three with alcohol-related cirrhosis with persistent varices and HVPG <10 mmHg after at least 5 years of ER were included. At evaluation, all patients had a patent portal vein and were compensated. The median platelet count was 129.5 (IQR 95-145) × 10
Conclusions UNASSIGNED
HVPG accurately reflects PPG in the context of HCV and alcohol-related cirrhosis regression. After ER, EV may persist despite HVPG <10 mmHg. The benefit of prophylaxis in patients with EV and HVPG <10 mmHg is unknown. Future studies with clinical endpoints are needed to validate our findings.
Impact and implications UNASSIGNED
Despite a favorable evolution after the removal of the etiologic factor, varices persist in some patients, and there is a lack of concise guidelines for the evaluation and management of portal hypertension in this population. Our research underscores the persistence of varices in the absence of clinically significant portal hypertension and significantly demonstrates the accuracy of hepatic venous pressure gradient (HVPG) in reflecting portal vein pressure in this specific patient group. These findings emphasize the crucial role of HVPG in the assessment of portal hypertension after etiologic factor removal and lay the groundwork for further investigation into clinical outcomes and the necessity of non-selective beta-blockers in individuals with persistent varices after the removal of etiologic factor.

Identifiants

pubmed: 39430576
doi: 10.1016/j.jhepr.2024.101170
pii: S2589-5559(24)00174-5
pmc: PMC11489337
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101170

Informations de copyright

© 2024 The Authors.

Auteurs

Pol Olivas (P)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).
Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.

Alexandre Soler-Perromat (A)

Radiology Department, CDI, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Luis Tellez (L)

Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.

José Antonio Carrión (JA)

Liver Section, Gastroenterology Department, Hospital del Mar, Institut Hospital del mar D'Investigacions Mèdiques, PSMAR, Universitat Pompeu Fabra, Facultat de ciències de la Salut i de la Vida, Barcelona, Spain.

Edilmar Alvarado-Tapias (E)

Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Gastroenterology Department, Hospital de la Santa Creu I Sant Pau, Institut d'Investigacions Biomèdiques Sant Pau, Barcelona, Spain.

José Ferrusquía-Acosta (J)

Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Unitat Hepatologia, Servei Aparell Digestiu, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain.

Sabela Lens (S)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.

Antonio Guerrero (A)

Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Servicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.

Ángeles Falgà (Á)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).

Pamela Vizcarra (P)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).

Lara Orts (L)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).

Valeria Perez-Campuzano (V)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).

Sarah Shalaby (S)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).

Sonia Torres (S)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.

Anna Baiges (A)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.

Fanny Turon (F)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).

Juan Carlos García-Pagán (JC)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).
Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.

Ángeles García-Criado (Á)

Radiology Department, CDI, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Virginia Hernández-Gea (V)

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Fundacióde Recerca Clínic Barcelona - Institut de Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Catalonia, Spain.
Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.
Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-RareLiver).
Depertament de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain.

Classifications MeSH